214476-89-8

Usage

Uses

Used in Pharmaceutical Industry:
3-Quinolinecarbonitrile, 4-hydroxy-6-Methoxy-7-(phenylMethoxy)is used as an anti-cancer agent for its ability to inhibit the growth of certain cancer cells in vitro. It has potential applications in the development of novel cancer therapies.
Used in Medicinal Chemistry Research:
3-Quinolinecarbonitrile, 4-hydroxy-6-Methoxy-7-(phenylMethoxy)is used as a compound of interest for further study in the field of medicinal chemistry, due to its unique structure and potential therapeutic properties.
Used in Inflammatory Disease Treatment:
3-Quinolinecarbonitrile, 4-hydroxy-6-Methoxy-7-(phenylMethoxy)is used in the investigation of its potential use in the treatment of inflammatory diseases, offering a new avenue for the development of anti-inflammatory drugs.

InChI:InChI=1/C18H14N2O3/c1-22-16-7-14-15(20-10-13(9-19)18(14)21)8-17(16)23-11-12-5-3-2-4-6-12/h2-8,10H,11H2,1H3,(H,20,21)

Upstream product

• 948028-56-6 (E)-methyl 4-(benzyloxy)-2-((dimethylamino)methyleneamino)-5-methoxybenzoate 
• 75-05-8 acetonitrile 
• 75167-86-1 2-(benzyloxy)-1-methoxy-4-nitrobenzene 
• 61324-40-1 3-benzyloxy-4-methoxybenzeneamine 
• 636-93-1 5-nitroguaiacol 
• 914490-09-8 (E)-3-(3-benzyloxy-4-methoxy-phenylamino)-2-cyano-acrylic acid ethyl ester 
• 100-39-0 benzyl bromide 
• 56441-97-5 methyl 4-(benzyloxy)-3-methoxybenzoate 
• 61032-41-5 methyl 4-(benzyloxy)-5-methoxy-2-nitrobenzoate 
• 61032-42-6 methyl 2-amino-4-(benzyloxy)-5-methoxybenzoate 
• 263149-09-3 methyl 4-(benzyloxy)-2-((dimethylamino)methyleneamino)-5-methoxybenzoate 

Downstream Products

• 1055963-51-3 8-(benzyloxy)-2-(1H-imidazol-1-yl)-9-methoxybenzo[c][2,7]naphthyridin-4-amine 
• 1055969-25-9 tert-butyl 2-(7-(benzyloxy)-3-cyano-6-methoxyquinolin-4-yl)-2-cyanoacetate 
• 214476-99-0 7-benzyloxy-4-chloro-6-methoxyquinoline-3-carbonitrile 
• 914490-16-7 N-[4-(3-cyano-7-hydroxy-6-methoxy-quinolin-4-ylamino)-phenyl]-benzamide 
• 914490-14-5 N-[4-(7-benzyloxy-3-cyano-6-methoxy-quinolin-4-ylamino)-phenyl]-benzamide 
• 914488-12-3 (S)-4-[4-(4-benzoylamino-phenylamino)-3-cyano-6-methoxy-quinolin-7-yloxy]-2-tert-butoxycarbonylamino-butyric acid cyclopentyl ester 
• 263171-60-4 7-benzyloxy-4-chloro-6-methoxy-quinoline-3-carbonitrile hydrochloride 

Relevant academic research and scientific papers

3-AMINOTHIENO[3,2-c]QUINOLINE DERIVATIVES, METHODS OF PREPARATION AND USES

The present invention relates to compounds according to Formula I: and salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, X, and Y are as defined herein. Methods for preparing co

BENZO[C][2,7]NAPHTHYRIDINE DERIVATIVES, AND THEIR USE AS KINASE INHIBITORS

The present invention relates to Benzo[c] [2,7] naph thy ri dine Derivatives of formula (I), compositions comprising an effective amount of a Benzo[c] [2,7]naphthyridine Derivative, methods for treating or preventing a proliferative disorder or an autoimmune disease, comprising administering to a subject in need thereof an effective amount of a Benzo[c] [2,7]naphthyridine Derivative, methods for modulating PDK-I activity, PKA activity, Akt activity, S6K activity, or PKC activity, comprising administering to a subject in need thereof an effective amount of a Benzo[c] [2,7] naphthyridine Derivative. The invention also relates to processes for preparing a Benzo[c] [2,7] naphthyridine Derivative.

Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors

This invention provides compounds of formula 1 wherein R1, G1, G2, R4, Z, X and n are defined herein, or a pharmaceutically acceptable salt thereof, which are useful as antineoplastic agents and in the treatment of polycystic kidney disease.

QUINOLINE AND QUINOXALINE DERIVATIVES AS INHIBITORS OF KINASE ENZYMATIC ACTIVITY

Compounds of formula (IA) or (IB), are inhibitors of aurora kinase activity: Formula (IA), (IB) wherein -L1Y1-[CH2]z- is a linker radical wherein Y1, L1 and z are as defined in the claims; R6 is C1-C4alkoxy, hydrogen or halo; W represents a bond, -CH2-, -O-, -S-, -S(=O)2-, or -NR5- where R5 is hydrogen or C1-C4 alkyl; Q is =N-, =CH- or =C(X1)- wherein X1 is cyano, cyclopropyl or halo; linker radicals L2 are as defined in the claims; R is a radical of formula (X) or (Y): wherein R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intracellular carboxylesterase enzymes to a carboxylic acid group; R4 is hydrogen; or optionally substituted C1-C6 alkyl, C3-C7 cycloalkyl, aryl, aryl(C1-C6 alkyl)-, heteroaryl, heteroaryl(C1-C6 alkyl)-, -(C=O)R3, -(C=O)OR3, or -(C=O)NR3 wherein R3 is hydrogen or optionally substituted (C1-C6)alkyl, C3-C7 cycloalkyl, aryl, aryl(C1-C6 alkyl)-, heteroaryl, or heteroaryl(C1-C6 alkyl)-; R41 is hydrogen or optionally substituted C1-C6 alkyl; and D is a monocyclic heterocyclic ring of 5 or 6 ring atoms.

USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS

This invention provides a method of treating or inhibiting colonic polyps which comprises providing a compound of formula (1); wherein R1, R2, R3, R4, X, Y, and n are defined hereinbefore, or a pharmaceutically acceptable salt thereof.

SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS

This invention provides compounds of formula (1) wherein R1, G1, G2, R4, Z, X and n are defined herein, or a pharmaceutically acceptable salt thereof, which are useful as antineoplastic agents and in the treatment of polycystic kidney disease.

Method of treating or inhibiting colonic polyps

This invention provides a method of treating or inhibiting colonic polyps which comprises providing a compound of formula 1 wherein:R1, R2, R3, R4, X, Y, and n are as defined hereinbefore, or a pharmaceutically acceptable salt thereof.

Substituted 3-cyanoquinolines

This invention provides compounds of formula I having the structure wherein G1, G2, R1, R4, Z, n, and X are defined in the specification or a pharmaceutically acceptable salt thereof which are useful as antineoplastic agents and in the treatment of polycystic kidney disease.